CONNECT WITH US:
Jan, 28 2019 13:00 JST
Singapore eDevelopment Ltd
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
SINGAPORE, Jan, 28 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has tested 3F Antimicrobial Fragrance which shows efficacy against tuberculosis. Tuberculosis is the leading cause of deaths from a single infectious agent, infecting about one quarter of the world's population.
The fragrance was shown to inhibit Mycobacterium tuberculosis (MTB), the causative bacterial agent of tuberculosis. Experiments were performed at ATCC as a custom service within its High Containment Laboratory under BioSafety Level 3 conditions. ATCC is a premier biological materials and information resource and standards organization with expertise in handling and experimentation on dangerous pathogens such as MTB.
Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives and a Nobel Prize nominee in 2015 and 2016 for his research on pandemic technology, leads research on the 3F Antimicrobial Fragrance. "3F works by taking advantage and exploiting the bacterial or viral sophisticated communication system called quorum sensing.
"In essence, we can utilise quorum sensing to instruct the bacterial or viral agent to shut down or stop replication.The 3F project was designed to provide a solution for open environment defence strategies, to prevent or suppress the transmission of aerosoled viral and bacterial particles that cause the spread of influenza, MRSA and tuberculosis in congested areas. The process has been demonstrated to be very effective."
"As a leading developer of authenticated cells lines and microorganisms, ATCC was honored to provide Global BioLife with custom susceptibility testing to determine if their product was able to kill MTB," said Dr. Manzour Hazbon, ATCC Senior Scientist. "This fragrance is very effective even in low concentrations, and an excellent candidate to treat tuberculosis, particularly important as there are few antibiotics effective in treating antibiotic-resistant tuberculosis cases."
Mr Chan Heng Fai, Executive Chairman of SeD said, "We are excited about the potential of this breakthrough in 3F Antimicrobial, and Global BioLife will step up in its continued efforts to provide cutting edge research into real solutions for global healthcare problems."
Dr. Roscoe M. Moore Jr, former Senior Assistant Surgeon General of the U.S. and highly-regarded public health expert who serves as Senior Scientific Adviser to Global BioLife, says "I'm excited about 3F's potential to address a global epidemic by providing safe and versatile protection layers."
"Tuberculosis is a global priority and Global BioLife's solution will help save lives on a global scale." Dr. Moore also served as Epidemic Intelligence Service Officer with the U.S. Center for Disease Control and Prevention, and as Chief Epidemiologist with the Center for Devices and Radiological Health in the U.S. Food and Drug Administration.
Also advising Global BioLife is Lieutenant Colonel William H. Lyerly Jr., a former Scientific Professional (ST) with the U.S. Government Civil Service and retired U.S. Army Medical Service Corps Officer with an extensive medical background including disaster relief, development, biodefense, interagency and civilmilitary cooperation and teaching.
"As TB's person-to-person spread requires only a small number of bacteria and transmission is most rapid in confined spaces, 3F efficacy is especially promising. And as multidrug-resistant TB continues a global health crisis and security threat, 3F's environmental intervention represents an effective and less-costly TB control strategy in high-transmission areas worldwide."
Global Biolife has partnered with Destum Inc to license its 3F technology to global manufacturers and distributers. 3F Mosquito, unlike repellents such as DEET, was developed as an additive to laundry detergents and lotions for layered protection against mosquitos. 3F Antimicrobial was developed as an additive for sprays, filters and dispersal systems in hospitals, transit and open areas to protect against bacteria and viruses.
Global BioLife (GBLI) is 70%-held by Global BioMedical, owned by Singapore BioMedical Ltd, owned by Singapore eDevelopment. 20% held by Global Research & Discovery Group LLC (GRDGS) and 10% by ASX-listed Holista CollTech. Tapping GRDGS & Holista expertise, GBLI pledges a concerted effort at prevention and treatment of neurological, oncology and immuno-related diseases. See www.globalbiolife.com.
GRDGS LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, visit www.globalrdg.com.
Singapore eDevelopment (SGX:V40), www.SeD.com.sg or
Source: Singapore eDevelopment Ltd
Sectors: BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
MITSUBISHI MOTORS' eK X & eK Wagon Kei Cars Win RJC Car of the Year 2020
Nov 13, 2019 19:39 JST
MHI Aero Engines Makes First Shipment of Domestically Assembled Pratt & Whitney GTF PW1200G Engine for the Mitsubishi SpaceJet
Nov 13, 2019 16:01 JST
Fujitsu Launches New PRIMEHPC Supercomputers Using Fugaku Technology
Nov 13, 2019 10:37 JST
Cray and Fujitsu Partner to Power Supercomputing in the Exascale Era
Nov 13, 2019 10:02 JST
MITSUBISHI MOTORS Introduces XPANDER CROSS
Nov 12, 2019 18:01 JST
DENSO Recognized with "Friend of ASEAN Award" at the ASEAN Business Awards (ABA) 2019
Nov 11, 2019 17:07 JST
Lexus Electric Debuts in China
Nov 11, 2019 16:38 JST
Fujitsu Expands Mid-career Recruitment
Nov 11, 2019 10:33 JST
Double Shanghai Podium for TOYOTA GAZOO Racing
Nov 11, 2019 09:11 JST
TOYOTA GAZOO Racing goes all-in for another title in Australia
Nov 08, 2019 19:33 JST
Honda Releases Consolidated Financial Summary for the Fiscal 2nd Quarter Ended September 30, 2019
Nov 08, 2019 15:09 JST
Mitsubishi Model A Selected as Historic Car by JAHFA
Nov 08, 2019 14:49 JST
BYD, Toyota Agree to Establish Joint Company for Battery Electric Vehicle Research and Development
Nov 07, 2019 19:12 JST
MITSUBISHI MOTORS Restyles Mirage and Attrage Compact Models
Nov 07, 2019 11:58 JST
Hitachi and Centre Leon Berard Cancer Center in Lyon to Launch a Research Collaboration in the Fight Against Cancer with AI
Nov 07, 2019 07:25 JST
Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo
Nov 07, 2019 05:09 JST
ULVAC launches Smartphone-Direct Pirani Gauge "SWU10-U"
Nov 06, 2019 17:00 JST
Showa Denko (SDK) Announces 2019 Third Quarter Financial Results
Nov 06, 2019 16:00 JST
NEC Showcases Industry-leading Digital Finance Solutions at Inaugural SFF X Switch 2019
Nov 06, 2019 15:11 JST
Suzhou Tongji Blockchain Research Institute and Fujitsu Research and Development Center start Research Collaboration on Blockchain Technology
Nov 06, 2019 11:45 JST
More Latest Release >>
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
November 15 2019 02:00 JST
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
October 29 2019 09:00 JST
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
July 24 2019 15:00 JST
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
June 12 2019 14:00 JST
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
November 07 2018 19:00 JST
Singapore eDevelopment Limited Announces Corporate and Business Update
June 18 2018 19:00 JST
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31 2018 18:00 JST
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
March 01 2018 14:00 JST
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
November 01 2017 18:00 JST
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
October 24 2017 18:00 JST
More Press release >>